PANews reported on May 6 that according to Fortune magazine, NewLimit, a biotech company co-founded by Coinbase founder and CEO Brian Armstrong, has completed a $130 million Series B financing round led by Kleiner Perkins. The company focuses on epigenetic reprogramming technology, repairing aging cells through AI and single-cell sequencing technology, and has made breakthrough progress in liver and immune system cell regeneration. Armstrong said that this technology is expected to double human lifespan again.
NewLimit uses artificial intelligence to reduce the cost of a single cell test to a few cents, greatly accelerating the research process. The company plans to launch non-human primate experiments in the next two years and seek permission for human clinical trials around 2028. Ilya Fushman, partner at Kleiner Perkins, pointed out that the technology is advancing anti-aging research at an unprecedented speed in the industry by combining large-scale genomics with cutting-edge AI.
